Emergent BioSolutions Entered into a Definitive Agreement with Chimerix to Acquire Tembexa (brincidofovir) Rights for Smallpox
Shots:
- Chimerix to receive $225M one-time up front in cash, ~$100M in milestones & is eligible to receive regulatory milestones related to SymBio's license for indications other than orthopox infections along with sales-based royalties during the exclusivity period of Tembexa. The transaction is expected to close at the end of Q2’22
- Chimerix is expected to receive a BARDA procurement contract in Q2’22. The acquisition expands & diversifies Emergent’s portfolio with the addition of Tembexa
- The acquisition builds on the Emergent’s capabilities with the US government’s strategy to address serious public health concerns. Tembexa is the 1st antiviral US FDA product for all age groups to treat smallpox
Ref: Globenewswire | Image: Emergent
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
